ecancer
M

EHA 2022 on R-CODOX-M/R-IVAC vs. Dose-Adjusted EPOCH-R in Newly Diagnosed High-Risk Burkitt Lymphoma

By ecancer FEATURING Martine Chamuleau
By ecancer FEATURING Martine Chamuleau
25 views
June 21, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Recommended

35:24

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

SOHO Highlights: State of the Art and Next Questions

G. Nowakowski

394 views

·

7 months ago
13:58

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

117 views

·

4 months ago
14:03

2023 SOHO® Brazil: "Moving Beyond CODOX - How Disease Features Can G…

SOHO Brazil 2023

J. Alderuccio

96 views

·

1 year ago
25:46

SOHO Highlights - State of the Art & Next Questions: Aggressive B-Ce…

SOHO Highlights: State of the Art and Next Questions

L. Sehn

75 views

·

1 year ago
23:26

SOHO 2023: Harnessing the Immune System in Patients With Lymphoma

SOHO 2023 Eleventh Annual Meeting

S. Ansell

28 views

·

11 months ago
24:14

Prognostication and Treatment of Burkitt Lymphoma in the Modern Era

19th Annual International Ultmann Chicago Lymphoma Symposium

A. Olszewski

94 views

·

2 years ago
13:50

SOHO 2021: Prognostication and Treatment of Burkitt Lymphoma in the …

Society of Hematologic Oncology Ninth Annual Meeting (SOHO 2021)

A. Olszewski

33 views

·

3 years ago
10:00

The Tumor Microenvironment Using Immune Checkpoint Inhibitors

2018 Pan Pacific Lymphoma Conference

J. Gribben

491 views

·

6 years ago
33:55

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lym…

ESO Lymphoma Course

A. Melnick

89 views

·

5 years ago
AUTOPLAY